# Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator

Study · id `cardio:ct-nct05527717` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05527717](<https://clinicaltrials.gov/study/NCT05527717>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05527717

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 560 participants.

## Technical summary

Registry record NCT05527717. Randomized; no masking; primary purpose treatment. Start 2022-11-16 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 560 participants (planned count; ClinicalTrials.gov record NCT05527717, source copy `cardio:ctgov-nct05527717-2024-11-06`, retrieved 2026-10-31)
- Started: 2022-11-16 (actual) (ClinicalTrials.gov record NCT05527717, source copy `cardio:ctgov-nct05527717-2024-11-06`, retrieved 2026-10-31)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT05527717, source copy `cardio:ctgov-nct05527717-2024-11-06`, retrieved 2026-10-31)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT05527717, source copy `cardio:ctgov-nct05527717-2024-11-06`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT05527717, source copy `cardio:ctgov-nct05527717-2024-11-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05527717-2024-11-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator
- Acronym: RESCUE-SHOCK
- Condition: Cardiogenic Shock
- Condition: Acute Myocardial Infarction
- Condition: Multi Vessel Coronary Artery Disease
- Condition: Extracorporeal Membrane Oxygenation
- Intervention (Procedure): Culprit lesion only PCI
- Intervention (Procedure): Immediate multi-vessel PCI
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: 2651de94830306ab4a8e04e1159a438fc7d10fc0c2c75318e293864a3e42539d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
